Armand Rousso Biotechnology News| Biotechnology Industry News| Biotechnology News Worldwide

Biotechnology News by
Armand Rousso R&D Labs

Creating new and successful businesses with world-class people and technologies - that is one thought that drives Armand Rousso - the visionary entrepreneur. Armand Rousso has seized numerous opportunities to launch new and successful business ventures in the world of High-Technology.

Biotechnology News by Armand Rousso R&D Labs

Biotechnology - Research and Markets - RSS Feed

Biotechnology publications from researchandmarkets.com

10/06/2008 10:23 PM

France Biotechnology Industry: Sector Report

This industry profile is an essential tool to help your company gain an in-depth knowledge and competitive advantage in the industry. The profile is an assimilation of insider knowledge, market characteristics and economic indicators. It analyzes the critical success factors in the industry - how the industry has evolved and how competitive dynamics have impacted market behaviour.

Sectional Highlights

- Structure of the industry, market size, and growth rates have been analyzed

- Value chain analysis categorizes the value-adding activities to develop low-cost differentiation strategies

- Trend analysis detects historical patterns that could help in forecasting future demand periods

- Critical issues are reviewed that may become a threat to the industry

- PEST analysis uses a framework of external factors for macro-environmental scanning of the industry to help in taking advantage of opportunities and making contingency plans for threats

- Competitive positioning of the industry leaders has been evaluated in terms of sales, profitability, stock trend and other performance indicators

Key Benefits

- Provides input for strategic business planning
- Targets business opportunities & risks
- Exploits competitive intelligence

Target Audience

- Investment Managers
- Venture Capitalists
- Management Consultants
- Research Companies
- Other Industry Professionals

10/06/2008 10:22 PM

German Biotechnology Industry: Sector Report

10/06/2008 10:22 PM

Australian Biotechnology Industry: Sector Report

10/06/2008 10:22 PM

Japanese Biotechnology Industry: Sector Report

10/06/2008 10:22 PM

Chinese Biotechnology Industry: Sector Report

10/06/2008 10:21 PM

Canadian Biotechnology Industry: Sector Report

10/06/2008 10:21 PM

Indian Biotechnology Industry: Sector Report

10/06/2008 10:21 PM

UK Biotechnology Industry: Sector Report

10/06/2008 10:20 PM

US Biotechnology Industry: Sector Report

10/03/2008 05:02 PM

The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2006)

This report looks at the biotech industries across European countries, with a focus on France, Germany, Netherlands, Sweden, Switzerland and the United Kingdom
Current Environment - Key Points
- In February 2006, the World Trade Organization (WTO) ruled that the EU's moratorium on genetically modified (GM) products, effective between June 1999 and August 2003, was illegal
Meanwhile, the EC struggled to enforce orders to some EU countries to lift national bans on GM products
- Market conditions were favorable for biotech stocks in Europe over the past six months but success was still very much on a case-by-case basis
Shares of biotech companies surged on news of consolidation and significant product milestones
- Major players in the industry recorded improved financials in 2005
Increasing worldwide demand for biotech products substantially boosted revenues
Continued consolidation in the sector added strength to European biotechs, enabling them to compete better internationally
- The period following the Initial Public Offerings (IPOs) for European biotechs proved favorable
There were 21 European biotech IPOs in 2005 compared with 17 in the US, according to UK venture capital (VC) group, Abingworth

Industry Profile - Key Points
- A recent comparative study by UK-based life sciences consultant, Critical I, showed that there are currently 1,980 biotech companies in Europe against 1,830 in the US
However, although US companies raise three to four times the amount of venture capital and spend triple the amount on research and development (R&D), they only generate about twice as much revenue as their European counterparts
- On September 22, 2005, EuropaBio, the European bioindustries association, launched a Healthcare Manifesto which calls for EU policy support for innovative healthcare (innovative medicines, orphan drugs, such as those developed to treat rare diseases, advanced therapies)
- White biotech (industrial biotech) is set

10/03/2008 05:02 PM

The Europe Biotechnology Sectors : A Company and Industry Analysis (October 2005)

This report looks at the biotech industries in Europe, with a focus on France, Germany, Netherlands, Sweden, Switzerland and the United Kingdom
Current Environment - Key Points
- As the US biotech industry forges ahead with increasing revenues and rising stock prices, Europe's industry is facing tough capital market conditions
However, more biotech companies are created every year in Europe than in the US
- The European Commission has taken the lead to spur biotech growth in the region but industry players and member states must take the initiative and make concerted efforts to take the industry to another level
- Major European biotech stocks continued to rise over the past six months despite shaky worldwide markets primarily due to concerns over rising oil prices
Investors reacted accordingly to positive financial, product and consolidation news
- Merger and acquisition (M&A) activity surpassed expectations in the past six months and even outstripped the US in the last few quarters
However, deals are bigger in the US than in Europe
- In the first nine months of 2005, six European biotechs went public
Europe outpaced the US in IPOs in the second quarter, having completed five IPOs compared to two on US exchanges

Industry Profile - Key Points
- Germany, the UK and France continue to lead the region's biotech industry but other nations such as Denmark, Switzerland and Sweden are catching up as they strive to become more prominent players
- The biotech industry in Europe continues to attract a healthy amount of venture capital and private investment
Deal amounts have become larger overall but the number of deals has declined
Investors prefer to direct funds into stable companies with a promising pipeline of products
- Biotech is still a priority at the European level
The European Union has doubled funding for research to more than -2 billion through the 6 th Research Framework Program that runs from 2001- 2006
Market Trends and

10/03/2008 05:02 PM

The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2005)

This report examines the biotechnology sectors in Europe, specifically the markets of France, Germany, the Netherlands, Sweden, Switzerland and the United Kingdom
Current Environment - Key Points
- The region's biotech regained its momentum and focus in 2004
This was largely driven by a positive flow of product news, stronger revenue growth, and a continuing consolidation wave
- Driven by advantages of efficiently structured healthcare systems and high accessibility of patient recruitment, the European Union's ten new member states offered impressive capacity for conducting clinical trials
- Demand for rapeseed oil to produce biodiesel surged over the past year, as biofuel production capacity rose dramatically thanks to the EU's measures to move toward a bioeconomy
- In early 2005, the EU was urged by the US to reconsider its rejection of genetically modified (GM) crop technology transfer to developing nations, claiming that the risks of growing biotech crops were being gravely overestimated in Europe
- A strategic rationale, rather than simple survival, drove consolidations
The growing number of transatlantic M&A deals implied that US companies were acknowledging the considerable value among European biotechs
- In 2004, 14 European companies made initial public offerings (IPOs), most of them UK-based biotechs
Experts anticipated a continuation of the flow of IPOs in 2005, albeit in an increasingly selective and value-sensitive market

Industry Profile - Key Points
- Within Europe, Germany, the UK, France, Switzerland, the Netherlands and Sweden remain the region's biotech leaders
- In 2004, the number of public and private biosciences companies across the six major European biotech nations was estimated at more than 2,000, compared with around 1,350 in 2003
- Nanotech is set to play a larger role in the region's biotech industry, as Europe is increasingly strengthening R&D in this rapidly growing, multidisciplinary sector that oft

10/03/2008 05:02 PM

The Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (June 2007)

This report examines the biotechnology industries in the Asia-Pacific, focusing on the markets in Australia, China, India, Japan, South Korea and Taiwan
Current Environment - Key Points
- Most Asia-Pacific biotech companies posted strong performances in the first half of 2007, with two thirds of the companies analyzed by Mergent seeing double digit growth in market capitalization between November 17, 2006 and May 15, 2007
- Consolidation continued to be a primary trend in the Asia-Pacific sector over the past six months, as biotechs sought to expand their reach and capture market attention
- Notable deals in the first half of 2007 included the acquisition of US biotech company Morphotek by Japan's Eisai (TSE: 4523), the acquisition of Nanjing Sike Pharmaceutical Group, Solid Success Holdings, by Singapore-listed AsiaPharm and India's Reliance Life Sciences- acquisition of UK biotech GeneMedix (LSE: GMX)
- In May, Australian biotechs Peptech (ASX: PTD) and EvoGenix (ASX: EGX), merged to form one of Australia's largest biotech companies specializing in the antibody and proteins therapeutics segment
- Partnering activity remained active as biotech companies and pharmaceuticals found it viable to maximize the probability of success and stay in business
- Despite a weak IPO market for biotechs, China's 3SBio (SSRX: NASDAQ), successfully listed on the NASDAQ on February 6, raising US$123 million

Industry Profile - Key Points
- The biotech industry in the Asia-Pacific is growing at a healthy rate, offering employment opportunities in areas ranging from drug research, drug development, life sciences and bioinformatics
- Governments and companies are putting in massive efforts to transition from competing on cost to developing homegrown innovative pipelines
- According to the International Service for the Acquisition of Agri-biotech Applications (ISAAA), Asian countries are increasingly investing in agricultural biotechnology research to help

10/03/2008 05:02 PM

The Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (July 2003)

Current Environment - Key Points
- The performance of most biotech companies in the Asia-Pacific was sluggish in 2003
However, a spate of good news in the US has revived interest in technology-related activities including biotechnology
- The Asia-Pacific biotech sector is worth just one-third of the NASDAQ biotech index
The market capitalization of 100 public Asia-Pacific biotech companies examined by Mergent was US$34.7 billion at May 30, 2003
- Many companies have put off listing because of the uncertainty lingering in investors- minds after the downturn in the world economy
There were no IPOs in the Asia-Pacific for biotechnology related stocks in the first half of 2003
Investors and analysts expect more IPO activity in H2 2003, especially in China
- M&A activity has fallen in the sector, and generally around the world
Industry Profile - Key Points - Asia-Pacific's biotechnology industries are at vastly different stages of development
Japan, Australia, Hong Kong, Korea and India each have at least 10 public companies for which biotechnology is the core business, while Taiwan, China and New Zealand have only a few
There are no public biotech companies in Thailand, Malaysia, Indonesia and the Philippines
- The Asia-Pacific is home to an estimated 12% of the world's public biotech companies
- The region's biotech companies fall into two categories: start-ups and established companies with business lines in other areas
- Governments are promoting biotechnology by establishing technology parks, funding companies and participating in research
- Intensive R&D has begun to find a cure for SARS, but is mostly government-led
Market Trends and Outlook - Key Points - Demand for improved agricultural yields is driving R&D of biotechnology agribusinesses products, although falling agricultural prices threaten to dampen growth and margins
- Demand exceeds supply in the world cereals market
The OECD predicts a rise in prices
Improved tech

10/03/2008 05:02 PM

The Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (June 2006)

This report examines the biotechnology industries in Asia-Pacific, focusing on Australia, China, India, Japan, South Korea and Taiwan
Current Environment - Key Points
- Mergent estimates that there are about 2,400 biotech and biotech-related companies scattered around the region, generating revenues of approximately US$40 billion
Most countries in Asia- Pacific continue to make considerable progress in developing vibrant biotech industries
- Biotech countries are capitalizing on a particular niche as a strategy to tap more effectively into the growing biotech market and enhance competitiveness
- Biotech company performance was weak toward the end of the first quarter and in the second quarter in the US this year but performance in Asia-Pacific was relatively strong
Biotechs in the region showed potential for significant returns
- Leading biotech companies continue to thrive despite facing tough and changing regulatory environment in China and Japan
- Biotech consolidation was slow to pick up in Asia-Pacific in the past six months but a number of strategic alliances and licensing deals took place between biotechs in Japan and Australia with those in North America and Europe

Industry Profile - Key Points
- The biotech industry in Asia-Pacific continues to flourish, propelled by the growth of the industry in Australia, China, India, Japan, South Korea, Taiwan, Singapore and Malaysia
- Healthcare biotech remains the primary focus of biotechs in Asia-Pacific driven by the increasing and ageing population and the lack of adequate treatments for some diseases
Agriculture biotech plays an increasingly important role in agricultural production in the region
- Venture capitalists are becoming more attracted to biotech as an area of investment
Governments continue to take the initial risks by funding biotechs at early stage to encourage the flow of venture capital and private investments into the nascent industry
- Government investment in b

10/03/2008 05:02 PM

Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (August 2008)

This report updates the previous Asia-Pacific biotechnology report, focusing on the markets in Australia, China and Hong Kong, India, Japan, South Korea and Taiwan
Current Environment - Key Points
- The rising cost of conducting research and carrying out trials in the west continued to shift investment to the east over the first half of 2008
- The stock market's decline affected biotech stocks, partly due to their higher risk profiles compared to other stocks
The Intersuisse Biotechnology Index in Australia, for example, reported the sharpest annual decline since its inception in 1996
- A landmark agreement between China's State Food and Drug Administration and the US Department of Health and Human Services, signed in Beijing in December, aimed to improve drug safety and quality control over Chinese produced pharmaceutical and biotech substances
- However, merger, acquisition and alliance activity remained strong in the first half of 2008
In a major transaction, Japan's Takeda Pharmaceutical (TSE: 4502) acquired US-based Millennium Pharmaceuticals (NASDAQ: MLNM) for US$8.8 billion in April
- Cash-rich drug makers continued to pursue acquisitions as they tried to cushion the impact of expiring patents in the coming years and fill out thin late-stage pipelines

Industry Profile - Key Points
- The biotech market in the Asia-Pacific was valued at US$14.9 billion for 2007 and is expected to grow by 10% in 2008, with Japan the largest contributor
- Governments in the Asia-Pacific are still providing most of the investment support to their biotech sectors
Currently, China is outspending the US on biotech
- Research and development (R&D) remain active in Australia, and encompass a range of research areas
- The Indian Government is considering switching to a pentavalent (five-in-one) vaccine in the country's immunization program, which will benefit some Indian biotech companies in the pentavalent vaccine business
The Government also undertook two major regu

10/03/2008 05:02 PM

The Europe Biotechnology Sectors : A Company and Industry Analysis (October 2007)

This report updates the previous European biotechnology report, focusing on the markets in France, Germany, the Netherlands, Sweden, Switzerland, and the United Kingdom
Current Environment - Key Points
- The past six months saw the maturing of European biotechs. A number of successful initial public offerings over the past six months suggested that biotechs are set to deliver products with potential for big returns. - US biotech indices, the NASDAQ Biotech index (+6.6%) and the AMEX Biotech index (+10.2%), outperformed the European WestLB Biotech index (+0.6%) between January 1 and May 15 this year. Leading biotechs recorded higher gains as the market capitalization of leading biotechs in Europe rose 5% between March 7 and September 21, according to a Mergent analysis. - Deal-making remained active in the past six months as drug giants snapped up promising therapies from smaller developers in order to beef up their pipelines. Qiagen (NASDAQ: QGEN) acquired US-based Digene for US$1.6 billion
- Seven European biotechs went public, raising a total of US$442 million, according to a Mergent analysis. The largest IPO was completed by Switzerland-s Addex Pharmaceuticals (SWX: ADXN) which raised CHF137 million (US$115.4 million) in May.
Industry Profile - Key Points
- A public-private partnership aimed at boosting new drug development in Europe, the Innovative Medicines Initiative (IMI), is on track to come into effect this year with total funding amounting to -2 billion (US$2.8 billion)
- Europe has taken a big step to aid SMEs, which presents another funding opportunity for biotech start-ups. The Eurostars Programme, under the EUREKA funding scheme, will be launched in October
- European Union (EU) ministers decided to forge ahead with a new EU system for centralized review of all gene, cell and tissue-based therapies in the EU by voting in favor of proposed regulations on advanced therapies. Europe will soon have

10/03/2008 05:02 PM

The Europe Biotechnology Sectors : A Company and Industry Analysis (October 2006)

This report updates the previous European biotechnology report, focusing on the markets in France, Germany, Sweden, Switzerland, the Netherlands, and the United Kingdom
Current Environment - Key Points
- The market capitalization of Europe's leading biotech companies increased 3.4% from US$16.6 billion to US$17.2 billion from March 8 to September 19 this year, according to a Mergent analysis
Large-cap biotechs performed well but investors increasingly moved away from small- cap companies
- Mergers and acquisitions between biotech firms or with pharmaceutical firms continued to be an important driver of growth, transformation and value creation
For many large firms, M&A are a response to anticipated patent expiration and gaps in a company's product pipeline; for small firms, they are often an attractive exit strategy
- On September 21, Europe's largest biotech company, Serono (SWX: SEO) was bought by Merck for US$13.3 billion
The cash deal created one of Europe's biggest drug groups, with a combined market value of around US$32 billion
- For the first time, Europe recorded a higher number of biotech IPOs than the US in 2005, according to BioCentury, a biotech industry publication
- From January to August, the region saw the completion of eight biotech IPOs, with US$209.6 million raised in total, according to Mergent

Industry Profile - Key Points
- A report in May by biotechnology industry consultancy, Critical I, found the number of biotech companies in Europe and the US was 2,163 and 1,991 respectively
The report found there were a higher percentage of young companies in Europe compared with the US
- In May, 16 research organizations from 12 European countries joined forces in industrial biotech (white biotech)
The network ERA Industrial Biotech (ERA-IB) will work to harmonize currently fragmented research policies
- European biotech companies face slow growth beyond the startup stage
According to Critical I, the capital available

10/03/2008 05:02 PM

Europe Biotechnology Sectors : A Company and Industry Analysis (May 2008)

This report updates the previous European biotechnology report, focusing on the markets in France, Germany, the Netherlands, Sweden, Switzerland, and the United Kingdom
Current Environment - Key Points
- Market conditions for biotechs in Europe became increasingly unfavorable over the past six months, with deteriorating values a good reason not to buy and product news stirring little interest
- Europe braced a new patent system known as EPC 2000, one of the biggest overhauls of the European patent system since the 1970s
- Over the last six months, opposition to genetically modified (GM) crops in Europe remained strong
France extended a temporary ban on growing GM maize citing concerns over risks to non-target organisms and development of resistance to toxins by the target organisms
- A Mergent analysis shows that the market capitalization of 14 European leading biotechs was down by 3.3% between September 21, 2007 and March 12, 2008
- Biotech merger and acquisition (M&A) activity in Europe slowed towards the end of 2007 but picked up in the first quarter of 2008
Difficult operating conditions resulted in takeover bids surrounding several UK's smaller biotech players
- The European biotech IPO window stayed opened throughout 2007
Despite the weakening general market in the second half, five companies completed their IPOs in the fourth quarter of 2007, raising US$143.1 million

Industry Profile - Key Points
- In the second half of 2007, European biotech companies raised a total of US$765.3 million in venture capital investment, according to a Mergent analysis
In January and February, venture capital funds invested a total of US$145.6 million into promising European biotech companies
- Cultivation of biotech crops continued to expand in the European Union (EU)
According to the International Service for the Acquisition of Agri-biotech Applications (ISAAA), Europe surpassed 100,000 hectares of biotech crops for the first time in 2007 with 77% growth
In

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (August 2005)

This report looks at the biotechnology industry in the United States and Canada
Current Environment - Key Points
- The US biotech industry ended on a high note in the closing months of 2004 but some high-profile product failures in recent months heightened safety concerns and pulled the sector down in the first quarter of 2005
- Leading companies in the US continue to record revenue growth and profits owing to stronger demand of products
They are also effectively discovering new indications for their products, especially in the area of oncology
- Biotech companies in both US and Canada are actively consolidating and forming partnerships
Pharmaceuticals in both countries are increasingly turning to biotech companies to fill their starving pipelines
- Canadian biotechs are showing signs of maturity with revenue increases of 21% in 2004 and a fall in losses by 30%
More and more companies are moving toward clinical trials and filing for product approvals

Industry Profile - Key Points
- The US continues to dominate the biotech industry globally, generating sales of $50 billion compared with $8 billion in 1992
Canada, though still falling behind the US, is ranked first in the world in terms of R&D expenditure and third in terms of revenue generation behind the US and Britain
- US biotech market capitalization rose to $400 billion in 2004 from $344 billion in 2003, up 16%, according to the index of US biotech companies tracked by Burril & Company, a life sciences merchant bank
- The US regulatory environment seems to be tightening to enhance drug safety and may lengthen future product approvals by the FDA
- Biotech financing in the US and Canada was relatively solid in the past six months, largely owing to biotech's strong underlying fundamentals
April and May saw a significant amount of venture capital poured into Canadian biotechs at home and abroad
- The biotech industry in the US and Canada continue to garner more and more investmen

10/03/2008 05:02 PM

The Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (December 2007)

This report updates the previous Asia-Pacific Biotechnology report, focusing on the markets in Australia, China, India, Japan, South Korea and Taiwan
Current Environment - Key Points
- Global biotech and pharmaceutical companies continued to outsource research, development and clinical trial activity to Asia-Pacific companies, boosting the industry further and further shifting global biotech attention to the region
- Competition from generic drugmakers and pricing pressures to develop new drugs continued to drive the need to outsource to lower cost but highly effective companies in the region
- The performance of the Asia-Pacific biotech sector over the last six months was dampened by the US subprime mortgage crisis, which affected the global market. Shares of leading companies Kyowa Hakko (TSE: 4151), Panacea Biotec (NSE: PANACEABIO), China Global BioChem (HKSE: 809) and Biota (ASX: BTA) were down in the second half of 2007 after posting gains in the first half. - Consolidation and partnering activities remained strong in the second half of 2007. The biotech industry in the region saw a number of mergers, acquisitions, outsourcing deals and cross-border discussions on intellectual property rights (IPR) licensing
- In the second half of 2007, two biotech companies, WuXi PharmaTech (NYSE: WX) of China and Saamya Biotech (BSE: 532905) were publicly listed.
Industry Profile - Key Points
- There are about 3,000 biotech companies in the Asia-Pacific generating more than US$40 billion, according to a Mergent analysis. China, Japan and Taiwan are the largest biotech markets in the region. China is expected to become the fifth largest drug market in the world by 2010
- In October 2007, New Zealand announced it would introduce a Biofuels Bill which will bring into force the biofuels sales obligation. The mandatory use will begin from 2008 and will comprise 3.4% of fuel company sales by 2012
- In October 2007, Q

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (March 2004)

Current Environment - Key Points
- The US biotech sector recovered rapidly in the second half of 2003 following encouraging product news and an improved outlook for the US economy
- The American Stock Exchange Biotech Index and the NASDAQ Biotech Index gained approximately 45% each in 2003
- Consolidation continued in 2003 with numerous M&A deals among biotech companies taking place during the year
- The Canadian biotech sector has grown significantly in recent years
The number of biotech companies grew 48% from 282 in 1997 to 417 in 2003
- Canadian biotech companies more than quadrupled their revenues between 1997 and 2002, from C$813 million in 1997 to C$3.6 billion in 2002
- The CBN Biotech Index gained 11.63% in the first nine months of 2003

Industry Profile - Key Points
- As of mid-April 2003, the market capitalization of publicly traded biotech companies in the US was $206 billion
- Biotech companies in the US raised $16.4 billion in new financing in 2003, an increase of 56% compared with the previous year
- The top five biotech companies spent an average of $133,600 per employee on R&D, equivalent to approximately 20% of their revenue
- The number of biotech companies in Canada grew by 11.2% in 2003, with 20% of them being publicly traded
- Canadian biotech companies spent C$1.3 billion on R&D investments in 2002, an increase of approximately 36.8% over R&D expenditure of C$950.5 million in 2001
- They raised C$527 million in 2002, a decline of about 60% compared with C$1.3 billion in 2001
Market Trends and Outlook - Key Points
- The increase in the world's population, a slowdown in crop rate improvement through conventional cultivation and a decline in the area of land available for food production have caused the rapid adoption of biotech by farmers around the world
- The ageing population has driven the increase in global healthcare expenditure, which has expanded the market opportunities for biotech drugs and treatm

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (February 2005)

This report looks at the biotechnology sectors in the United States and Canada, including the research, development and manufacturing and marketing and distribution segments
Current Environment - Key Points
- In 2004 the US biotech industry saw a greater number of profitable biotech firms with promising drugs in pipelines
- In the third quarter of 2004, most leading biotech firms in the US reported encouraging financial results
Sales growth continued to be driven primarily by core business segments and key products
- Acquisitions in the US biotech-pharmaceuticals industry during the first half of 2004 nearly doubled to 315 from 177 in the second half of 2003
- The Canadian biotech sector moved towards fuller maturity, following a rebound in 2003
Firms accelerated product manufacture; some more than doubled their investments in research and development
- The majority of leading Canadian biotechs displayed continued growth in financial performance, mainly driven by positive market demand for companies- key leading products

Industry Profile - Key Points
- The US remains the global biotech front-runner in terms of revenue generation, with a sector worth more than US$35 billion a year
- The US accounts for nearly two thirds of all biotech crops grown globally and agricultural biotech remains a major area for US biotech companies
- The booming US biotech sector remains a major employer of the American workforce
By 2014, the industry is expected to be responsible for over 3,600,000 jobs in total
- Canada has more biotech companies per capita than any other country, and the industry ranks third globally behind the US and the UK in biotech revenues
- Sustained growth in the Canadian biotech industry is helping venture investment in the industry to pick up, albeit at a gradual pace
Market Trends and Outlook - Key Points
- The US is becoming a global leading force in the development of transgenic animals (animals with genes inserted from

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (August 2006)

This report updates the previous North American biotechnology report, focusing on the markets in Canada and the United States
Current Environment - Key Points
- Biotech continues to be a top priority in North America, with dozens of states investing money and resources into biotech R&D and offering attractive incentives to companies to invest
- Biotech performance was sluggish in North America in the first half of 2006 despite impressive performances delivered in 2005
The AMEX Biotechnology Index fell 3.8% while the NASDAQ Biotechnology Index fell by 7.25%, The S&P/TSX Capped Healthcare Index was down by 3.5%
Overall, the biotech sector underperformed the broader market during the period
- Based on a Mergent analysis, the market capitalization of leading companies fell by 10.6% in the US and 17% in Canada over the first six months of 2006
- In the first half of 2006, the US biotech sector saw 32 M&As valued at about US$3.3 billion
This was significantly lower than the US$11 billion recorded in the first half of 2005 due to several large acquisitions which took place during the period
In Canada, there were nine such deals totaling C$1.04 billion (US$0.92 billion)
Biotech partnering activities continued at a torrid pace in North America
- Biotech IPOs picked up in the first half of the year but only in the US
Ten biotech companies completed their IPOs, raising US$423.30 million against US$289 million raised by six biotech companies in the first half of 2005

Industry Profile - Key Points
- According to the Biotechnology Industry Organization (BIO), there are currently about 1,444 biotech companies in the US, employing about 187,000 people
San Francisco-based life sciences merchant bank, Burril & Co reported that in 2005, US public biotechs generated revenues of US$71.5 billion, an increase of 20% from the US$59.5 billion in 2004
- Canada ranks second after the US in terms of the number of biotech companies with nearly 500 altogethe

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (August 2007)

This report updates the previous North American biotechnology report, focusing on the markets in Canada and the United States
Current Environment - Key Points
- Congress is close to creating a way to approve generic copies of biotech drugs. Some of the industry-s top products will run out of patent protection in seven or eight years
- Generic manufacturers that have long lobbied to get into the biologics business are now allied with health plans and legislators fighting to reduce health care costs
- In the first half of 2007, shares of traditional drug makers outperformed biotech, a reversed situation of the recent past, when investors favored the fast-growing but risky biotechs over major pharmaceutical stocks. - The NASDAQ and AMEX biotech indices both underperformed the NASDAQ Composite and Dow Jones Industrial by rising only 2% and 3.5% respectively as of July 11. US biotech giants, Amgen (NASDAQ: AMGN) and Genentech (NYSE: DNA) took a beating. Similarly, Canadian biotechs also saw a rocky first half. - The US biotech sector continued to see active consolidation and partnering activities with traditional large pharmaceutical companies. A Mergent analysis showed that in the first half of 2007, there were 21 biotech mergers and acquisitions (M&As) in the US, worth about US$28.2 billion. Over the same period in Canada, there was no major biotech M&A. - Despite the tough IPO climate, 11 American biotech companies completed their initial public offerings (IPOs) in the first half of 2007, raising US$609.8 million in total, according to a Mergent Analysis. No biotech IPOs were seen in Canada and two Canadian biotech companies withdrew their planned IPOs

Industry Profile - Key Points
- The US biotech industry continues lead the world in 2006 in terms of both products and revenues. According to professional services firm Ernst & Young, US public biotech company re

10/03/2008 05:02 PM

The Europe Biotechnology Sectors : A Company and Industry Analysis (October 2004)

This report looks at the biotechnology sectors in the European markets of France, Germany, The Netherlands, Sweden, Switzerland and the United Kingdom
Current Environment - Key Points
- There is an increasing gap between large and small biotech companies, primarily due to insufficient backing from venture capitalists to struggling, privately-financed firms
- Nevertheless, industry experts believe that the European Union's (EU) new member states could strengthen Europe's position in the biotech sector and the overall life sciences industry
- Many large pharmaceutical companies are collaborating with biotechs to exploit their drug- development capabilities
In return, pharmaceutical companies are offering biotechs funding, manufacturing and marketing services, and securing regulatory approval for products in development
- After a four-year financial drought, the European biotech industry is experiencing an investment upturn, which began in 2003
Since March, four biotech companies have posted initial public offerings (IPOs) - raising a combined US$345.3 million

Industry Profile - Key Points
- Although Europe has a strong, world-class biotech science base, the sector still lags in the number of commercial, scientific advances
- A fragmented market, coupled with pressure to lower manufacturing and R&D costs, and a climate that does not encourage or reward innovation, is also hindering the sector
- A lack of funding and investor confidence has forced companies to cut costs and research
Revenues for the European biotech industry fell 12% to about -11.3 billion (US$13.62 billion) in 2003
- Germany, the UK, France, Switzerland, the Netherlands and Scandinavian nations, especially Sweden, continue to be Europe's s biotech leaders
- The number of biotech companies in the major European countries has fallen from 1,340 in 2002 to 1,305 in 2003
- During the second quarter of 2004, investment in biotech and healthcare reached -482 million (US$580

10/03/2008 05:02 PM

The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2007)

This report looks at the biotech industries in Europe, with a focus on France, Germany, Netherlands, Sweden, Switzerland and the United Kingdom
Current Environment - Key Points
- The European biotech sector as a whole fared well over the past six months, fueled by good news and further M&A speculation
- Following the acquisition of Serono (SWX: SEO) by Merck (NYSE: MRK) in September 2006, Merck announced the official launch of Merck Serono (SWX: SEO) on January 8 this year
Merck Serono will operate as a biotech division within the pharmaceuticals business sector of Merck
- Deal-making continued at a torrid pace in Europe over the past six months, with a long line of pharma companies increasingly willing to pay a premium for a stake in a promising therapeutic program
- In December 2006, GlaxoSmithKline (NYSE: GSK) broke an industry record by licensing a drug for leukemia from Genmab (CSE: GEN) for US$2.1 billion
In the same month GSK announced a deal to acquire private drug discovery outfit Domantis for US$453 million
- Biotech IPOs in Europe showed signs of improvement
Nine European biotech companies listed between September 2006 and March this year
The total amount raised was US$446.8 million, according to a Mergent analysis

Industry Profile - Key Points
- A report released in May by Critical I, a biotech industry consultancy, demonstrates a number of consequences arising from an insufficient and unsustainable stream of finance for biotechnology
The report put the respective number of companies in Europe and the US at 2,163 and 1,991
However, American biotechs are larger, better financed and more profitable
- There have been several important developments in healthcare biotechnology in the past year
They include the implementation of the Advanced Therapies Regulations, the completion of the biosimilars framework and the setting up of the European Medicines Agency's (EMEA) dedicated office for SMEs
- The Seventh Research Framewor

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (February 2006)

This report looks at the biotechnology industry in the United States and Canada
Current Environment - Key Points
- Large-cap biotechs in the US made big gains in 2005 as reflected by the 27% increase of the AMEX Biotech Index
The NASDAQ Biotech Index, which represents smaller biotechs, mirrored the broader market with its 3% gain in the year
- The second half of 2005 saw leading biotechs in North America turn in an excellent performance demonstrated by rising revenues, stable cash position, active research and development (R&D) activities and strong growth prospects
- The news about a potential outbreak of the avian flu has shaken the long dormant vaccine business
It has driven a consolidation of the vaccine business in North America while spurring efforts in biotech companies to find new ways to develop and manufacture vaccines much more efficiently
- In the second half of 2005, there were eight biotech IPOs completed in the US and two in Canada

Industry Profile - Key Points
- There are currently about 1,473 biotech companies in the US
The US biotech industry has been growing at double digit rates annually according to Biotechnology Industry Organization (BIO)
In 2004, the industry generated sales of $46 billion, up from $8 billion in 1992
- Canada has about 450 biotech companies
It is ranked third behind the US and UK in terms of revenues, but is ranked first in the world in terms of R&D expenditure per employee according to BIOTECanada
- In the US, total financing increased consistently during each successive quarter up until the third quarter in 2005
Total investment in venture capital (VC) in the third quarter was up 7% from the corresponding quarter in 2004, according to Burril & Co, a San Francisco-based global life sciences merchant bank
- In Canada, VC investment in life sciences tracked by Canadian VC expert, Macdonald & Associates, fell 32% in the third quarter of 2005 from the corresponding quarter in 2004, as inve

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (April 2003)

Covering the top public biotechnology companies in the areas of biopharmaceuticals, agricultural biotechnology and genomics in the United States and Canada
Also includes comprehensive industry analysis and market trends
Current Environment - Key Points
- The combined total revenue of 20 of the top revenue earning biotech companies in the US in 2001 was approximately $11,501,584,000
- In the 12 months between January 2002 and January 2003, the NASDAQ Biotech Index, dropped 40%, underperforming the NASDAQ Composite Index
- Biotech IPOs have slowed down considerably in the US: in 2002, two years after the height of the biotech IPO boom, only two Washington State-based biotech companies had successful IPOs, compared with 25 IPOs in 2001 and 80 in 2000
- In 2002, the US industry bettered 2001's performance, when $5.7 billion in new capital was invested in the industry, $250 million more than in all of 1998
- Although 2002 witnessed 19 US product delays, the big picture for biotech remains positive
- US pharmaceutical-biotechnology alliances have risen in value from under $1 billion in 1997 to more than $3 billion
- Revenues in the Canadian sector more than doubled in the 1997-2001 period
Between 1999 and 2001 revenues increased from $709 million to $827 million
- Therapeutics is the largest segment in Canada at 57% up from 37%, followed by agriculture at 15% down from 26%, and diagnostics at 10% down from 22% between 1997 and 2001

Industry Profile - Key Points
- Market capitalization, the total value of US publicly traded companies- market prices, was $224 billion as of May 2002
- The high cost of R&D, intense competition, long development lead times and short patent protection periods are putting increasing pressures on executives to find more efficient discovery platforms and development paradigms
- Functional genomics is expected to be a key focus of biological exploration in the 21st century and beyond
- The US biotech industry spent $1

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (September 2004)

This report looks at the biotechnology sectors in the United States and Canada, including the research, development and manufacturing and marketing and distribution segments
Current Environment - Key Points
- The strong rebound in the global biotech industry continued into the first half of 2004, driven largely by product successes
Publicly traded biotech companies registered an improvement of 65% in their net losses while increasing their employment by 9% during the year
- In the US, the increase in new product approvals and promising results in clinical trials of experimental drugs have accelerated the recovery of the biotech sector
- Pharmaceutical companies in the US are increasingly carrying out mergers and acquisitions with biotech companies to fill their pipelines with new drugs and replicate their initial successful earnings
- The Canadian biotech sector experienced a strong rebound in 2003, with revenues of public biotech companies climbing 18% to US$1.73 million
- While the Canadian biotech sector is fundamentally strong, its continued financial health faces significant challenges
Cash positions of public biotech companies continued to deteriorate and net loss of the sector surged 123% to US$586 million in 2003

Industry Profile - Key Points
- As of mid March 2004, the market capitalization of publicly traded biotech companies in the US was $311 billion, up nearly 51% from $206 billion recorded in 2003
- Venture capital investment in the US biotech sector has remained robust over the last few years
Investments in the biotech sector accounted for more than 20% of all venture capital investments in the US in the first quarter of 2004
- Employment in the biotech sector grew 6.3% in 2003 after increasing by 12% in the 2000 to 2002 period, representing the fastest growth for any major industry in the US
- The Canadian biotech industry ranks second only to the US in the number of biotech companies, and generates revenues that r

10/03/2008 05:02 PM

The Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (December 2005)

This report examines the biotechnology industries in Asia-Pacific, focusing on Australia, China, India, Japan, South Korea and Taiwan
Current Environment - Key Points
- Asia-Pacific nations continue to promote the growth of biotech largely through increased public investment
- Australia is the most advanced biotech market, although biotech is growing in China, India, Malaysia, Singapore, Taiwan and South Korea
- Biotech share performances mirrored the successes of their peers in the US
The NASDAQ Biotech Index rose 11.6% this year, higher than the 10.8% increase recorded by the NASDAQ Composite
Contributing to the rise was news on domestic economic recovery in the region
- Biotech consolidation and alliance activities in Asia-Pacific continued but at a slower pace compared with the US and Europe
- Biotechs and pharmaceuticals still prefer to enter the Asian market through joint ventures, strategic alliances and licensing agreements

Industry Profile - Key Points
- Mergent data showed that the Asia-Pacific biotech industry is valued at about US$101 billion
At present, there are about 2,000 biotech and biotech-related companies in Asia-Pacific
- Healthcare biotech is the predominant focus in the region, engaging between 40% and 75% of biotech activities
Stem cell research is accelerating in Asia-Pacific
- China and India are leading the way in developing transgenic crops in the region
Adoption of biotech in agriculture has recently spread to Philippines, Pakistan and Bangladesh
- Nations are ramping up production of biofuel as an alternative source of energy to counter energy shortage
- Financing climate remains a barrier to biotechs in the region
Venture capital investors are risk- averse toward biotech companies and banks are reluctant to lend to young biotechs
However, efforts are underway to stimulate venture capital investments
- Governments have planned to increase biotech investments in Australia, China, India, Taiwan, Sout

10/03/2008 05:02 PM

The Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (December 2006)

This report examines the biotechnology industries in the Asia-Pacific, focusing on the markets in Australia, China, India, Japan, South Korea and Taiwan
Current Environment - Key Points
- Biotech shares in Australia recovered in the second half of 2006, after falling in April and May
The Intersuisse Biotech Index, which tracks the performance of 80 biotech stocks in Australia, gained 7.6% in October with gains exceeding declines by almost two to one
- Shares of biotech companies in India, Japan and China declined in the second half of 2006
From the third quarter until mid November 2006, major biotech shares continued to be volatile, but were edging higher
- The biotech sectors in China and India continue to maintain their lead, with both countries boosting research &development (R&D)
China is now moving from being purely a low-cost manufacturing base into a market in which companies are increasingly using R&D and clinical trials
- Over the past six months, biotech consolidation activity in the Asia-Pacific paled in comparison to the US and Europe
A landmark deal spearheaded by a Singaporean biotech confirmed the ability of biotech companies in the region to establish themselves as major players

Industry Profile - Key Points
- The region's biotech industries are maturing rapidly, primarily because of a commitment and investment by governments to develop their biotech industries into engines of economic growth
- In developing countries such as Thailand, Malaysia, Indonesia, the Philippines and Vietnam, the main thrust of biotech development is toward researching and developing agricultural products
In more advanced markets such as Australia, Singapore, Taiwan, South Korea and Japan, the focus is toward making advancements in genetic research and human healthcare
This is due to the increasing and ageing populations, government health policies and unmet medical needs
- South Korea is beating Japan and China in its push into the emergi

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (February 2007)

This report looks at the biotechnology industry in the United States and Canada
Current Environment - Key Points
- Biotech had an improved final quarter in 2006 compared to the third quarter
The NASDAQ Biotech Index was up by nearly 7% over the six months to the end of the year
The Amex Biotech Index grew 12.8% over the same period
- The Canadian biotech sector, which faltered in the second quarter of 2006, continued to decline in the third quarter but rebounded in October and November as falling oil prices pushed stocks higher
- There was a surge in the values of biotech buyouts over the past six months
A Mergent analysis showed that in the second half of 2006, there were about 17 biotech M&As in the US worth an estimated US$8.80 billion
The amount was more than double the US$3.3 billion recorded by 32 companies in the first half
- In the second half of 2006 the Canadian biotech sector saw six biotech M&As, with a total value of US$624.5 million
- In the US, five biotech companies completed their IPOs in the second half of 2006
The US$299.5 million raised from IPOs was down 29% from the US$423.3 million raised in the first half of 2006
Only one biotech company managed to get listed in Canada in the second half of 2006

Industry Profile - Key Points
- In 2006, industrial biotech was given a boost in the US, mainly due to breakthroughs in the production of bioethanol and President Bush's Advanced Energy Initiative (AEI)
- On December 12, 2006, the Senate passed legislation that aims to help create cellulosic biomass ethanol plants
- The Securities and Exchange Commission (SEC) announced plans to ease auditing standards for small, publicly traded companies
- In the US, the biotech sector enjoyed greater finance levels over the past six months
A Mergent Analysis showed that in the second half of 2006, 35 biotech companies raised US$1,018 million in venture capital
- In October 2006, the Canadian Biotechnology Advisory Committee (C

10/03/2008 05:02 PM

The North America Biotechnology Sectors : A Company and Industry Analysis (October 2003)

Current Environment - Key Points
- The combined total revenue of ten of the top revenue-earning biotech companies in the US in 2002 was approximately $200,348,498,000
- Although the biotech Index hit an all-time low of 464.93 in September 2002 and peaked in August 2003 at 740.84, underlining the fact that 2002 was a brutal year, there has been a rapid recovery in 2003
- Major end markets include biotech crops, which are generally accepted by American consumers, although doubt persists for Europeans; as well as the biopharmaceutical sector, which is introducing a flurry of new drugs to the healthcare industry
- Worldwide biotech merger and acquisition volume increased from $1.58 billion in 2001 to $5.22 billion in 2002 with the number of transactions increasing from 13 in 2001 to a record 18 in 2002
- Recent estimates from the Biotechnology Industry Organization indicate that biotech funding from biotech-pharma alliances exceed $5 billion a year, representing an annual growth rate of more than 40%
- Several Canadian biotech companies are changing the future landscape of the Canadian biotech industry
Despite some major successes, the main concern lies in the viability of biotech companies with less than 18 months of cash on hand
- Canadian public company revenues reached $1,466 million, up 44% over 2002
In 2002, market capitalization decreased by 31% to $8,867 million from $12,909 million in 2001

Industry Profile - Key Points
- As at mid-April, the total value of US publicly traded companies- at market prices was $206 billion
- Encouraging study results on biotech drugs, coupled with a new US Food & Drug commissioner and a general willingness to take on riskier investments, has sent biotech stocks up since the start of 2003, which bodes well for the venture capital market
- The top five US companies spent an average of $133,600 per employee on R&D, approximately 20% of their revenue, while pharmaceuticals spent only 11%
- The FDA's f

10/03/2008 05:02 PM

The Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (June 2005)

This report examines the biotechnology sectors in Asia-Pacific, focusing on the key markets in Australia, China, India, Japan, South Korea and Taiwan
Current Environment - Key Points
- The Asia-Pacific biotech industry presented strong competition to its rivals in North America and Europe
Governments in many Asian countries increasingly placed biotech higher on their agendas
- Many Asian nations expressed enthusiasm to advance stem cell research in the region, ignoring the UN's declaration against human cloning in March 2005
- Much of Asia displayed growing acceptance and more extensive adoption of biotech crops, as compared to industry counterparts in the EU
- From the second half of 2004 up to the first quarter of 2005, major industry players in Asia-Pacific reported another period of solid financial performance
- Overall, there was a renewed sense of optimism among many of the industry's leading firms
- The past six months saw continued active consolidation activities in the Asia-Pacific biotech industry albeit at a lower level than in the US and most EU nations
Countries such as Australia, China, India and Japan led the region in this consolidation wave

Industry Profile - Key Points
- Australia, India, China, Japan, South Korea, Taiwan and New Zealand remain the region's main industry leaders, while Singapore, Thailand and Malaysia are aggressively gaining ground in this highly competitive sector
- The Asia-Pacific biotech industry is estimated to be worth more than US$100 billion and Asia is currently the second largest biotech market in the world, after North America
- In Asia-Pacific, biotech development aims mostly at increasing agricultural yields to sustain a rapidly growing population
- Along with global trends, Asia-Pacific is experiencing rapid advancements in biomedical/ biopharmaceutical research, indicating that the environment for nurturing the biomedical/ biopharmaceutical industry is gradually maturing
- Government

10/03/2008 05:02 PM

North America Biotechnology Sectors : A Company and Industry Analysis (February 2008)

This report updates the previous North American biotechnology report, focusing on the markets in Canada and the United States
Current Environment - Key Points
- The biotech industry finished 2007 on a good note
In the second half, biotech outperformed the general market with the NASDAQ Biotech Index gaining 3%, ahead of the Dow Jones which declined by 2% and the NASDAQ Composite which gained less than 1%
- Shares of biotech heavyweights, Amgen (NASDAQ: AMGN) and Genentech (NYSE: DNA) fell 21% and 11% respectively in the second half of 2007
- The Canadian biotech sector, however, continued to decline in the second half of 2007
The S&P/ TSX Capped Health Care Index fell 22% in the second half
- In the US, M&As continued to dominate the news
A Mergent analysis showed that in the second half there were 19 biotech M&As in the US, worth about US$10 billion
Consolidation was on a slowdown in Canada
- Biotech IPOs were slow in the second half of 2007 and turned in weak performances
Five American biotechs completed their IPOs, raising about US$150 million, a quarter of the amount raised in the first half of 2007
- There was no biotech IPO in Canada over the same period
Vancouver-based Chemokine Therapeutics decided to withdraw its public offering in December citing poor conditions in the financing market

Industry Profile - Key Points
- As of December 31, 2005, there were 1,415 biotechnology companies in the US, of which 329 were publicly held, according to the Biotechnology Industry Organization (BIO)
According to a Mergent analysis, US public biotech companies generated revenues of US$52.9 billion as of December 31, 2006
- In the second half of 2007, venture capitalists funneled US$1,130 million into 47 American biotech companies according to a Mergent analysis, representing an 11% increase from the US$1,018 million raised by biotechs in the second half of 2006 - In August 2007 , The US Patent and Trademark Office (PTO) issued new rules aimed at stream

10/03/2008 05:02 PM

The Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (December 2003)

Current Environment - Key Points
- From May 30 to October 31 2003, the total market capitalization of 100 publicly listed Asia-Pacific biotechnology companies tracked by Mergent rose by 8.88%
- Except for Korea, biotechnology companies operating in the region enjoyed overall increases in their share prices, resulting from an upwards trend in US biotechs that filtered through to Asia
- Expectations of a rise in the number of biotechnology IPOs in the second half of 2003 have not been met, with the majority of new listings being in property, communications, electronics, resources and non-biotech IT sectors instead
- Asia-Pacific biotech companies are increasingly forming alliances with foreign partners to enable their respective products to reach new markets
Industry Profile - Key Points - Asia-Pacific is home to an estimated 12% of the world's public biotech companies
Mergent data shows the Asia-Pacific biotechnology sector is worth around US$80 billion
Start-ups and companies extending business lines are common among Asia-Pacific biotechs
- Governments are continuing to promote biotechnology in their respective industries by establishing technology parks, funding companies and participating in research
- Government-led research into finding a cure for SARS has resulted in detection kits being developed in Taiwan, Hong Kong, China, Japan and Singapore
SARS is expected to return during the northern winter 2003
- Despite SARS, foreign direct investment (FDI) into China for January to September was US$40.2 billion and is expected to top US$57 billion in 2003
The outbreak did not hamper investment in Asia-Pacific
Market Trends and Outlook - Key Points
- Biotechnology has the potential to solve problems including diminishing arable and permanent crop land
The demand for improved agricultural yields has risen
Developing countries (many of which are in Asia-Pacific) are expected to contribute more to world cereal output than developed cou

10/03/2008 05:02 PM

The Asia-Pacific Biotechnology Sectors : A Company and Industry Analysis (December 2004)

This report discusses the biotechnology sectors in the Asia-Pacific, focusing on Australia, China and Hong Kong, India, Japan, South Korea and Taiwan
Current Environment - Key Points
- Most Asia-Pacific governments still view the biotechnology sector as having great growth potential
- Most governments are keen to foster R&D to acquire patents
However, the region still lacks sufficient intellectual property right protection for drug innovation compared with developed countries
- Asia-Pacific countries are mostly concentrating on bio-pharmaceutical, bio-medicine, and bio- agriculture, especially genetically modified organisms (GMO)
- Food research continues to be a priority, with the region home to more than half the world's population
- With the acceptance of bio-related products in the region, the industry reported improved financial results in 2004
- Although the bio-pharmaceutical industry carries high-risk, it is one of the fastest growing sectors in the region
This is especially the case in India and Korea
Industry Profile - Key Points - Most countries in Asia-Pacific have industry development plans, which set ambitious targets for industry growth, typically either by developing research and its commercialization or by promoting specific market segments
- With the region forecast to be home to ten billion people in 2030, biotechnology development is aimed at increasing agricultural yield to sustain the growing population
- The environment for nurturing the bio-medical industry is becoming more mature globally, but the Asian scene is still in its early stages of growth
- Asia-Pacific countries are now more proactive in upgrading their biotechnology sectors and there continues to be a surge of interest in biotechnology, with numerous conferences held across the region
Market Trends and Outlook - Key Points
- A ban on stem cell research by most European countries and North America (except the state of California) has led to companie

10/03/2008 05:02 PM

The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2004)

Current Environment - Key Points
- A challenging economic climate has contributed to a global decline in investments and a cut in bioscience funding, placing financial pressure on Europe's biotech industry
- The biotech industry is also struggling with resistance to the use of genetically modified organisms (GMOs), in particular bio-crops
- There is healthy growth in the number of life sciences publications in four main areas: clinical medicine, basic life sciences, biomedical and biological sciences
- There is growth in the collaboration between biotech companies and pharmaceuticals
- Several areas of biotech research are being particularly targeted in the next few years: genomics and biotech for health, nanotechnology, and food quality and safety
- As investors turn away from the industry's uncertain returns, biotech companies are using mergers and acquisitions to generate cash and ensure survival and growth
- In 2002, there were only three European biotech IPOs, which raised a total of US$34.7 million (-28.45 million) - a far cry from the 2000 regional record of US$2.2 billion (-1.80 billion)

Industry Profile - Key Points
- European nations hurrying to establish home-grown biotech industries are facing challenges in obtaining venture capital, conservative attitudes towards risk and negative public opinion (particularly in the agricultural biotech field)
- The UK, Germany, France, Switzerland, the Netherlands and Scandinavian countries are leading the biotech revolution across Europe
- By mid-2003, the number of companies in the life sciences industry had grown almost four-fold to more than 1,500
- The European biotech field is focused on three emerging areas: green biotech, white biotech and healthcare biotech
- Europe spent nearly 2% of its GDP on R&D between 2000 and 2002, with the highest ratios in Sweden and Finland
- Europe's venture capital investment fell 45% to about -5.4 billion (US$6.59 billion) in 2002
- Effective Apri

09/30/2008 09:41 PM

Laboratory Equipment Market Report 2008

The UK market for laboratory equipment, which includes research equipment/instrumentation and laboratory consumables, was worth an estimated £2 79bn in 2007, having increased in value by 31 2% across the review period (2003 to 2007) Year-on-year growth over the period averaged 7%, reflecting a sharp...

09/30/2008 04:58 PM

The Research Report on China’s Plant Extracts Market, 2008

The report is a high-valued reference for investors to know the status quo of Chinese plant extract market and the development trend It helps investors evade the investment risks and grasp opportunities through synthesized analysis on raw materials, production, demand, and investment Plant extracts...

09/26/2008 07:42 PM

North American and European Biometrics Market - Investment Analysis

This research service provides an insight into the growth opportunities for the NA and EU Biometrics markets The research service also includes an introduction to segment analysis, growth monitor and the score cards The research service gives an overview of the industry economics that operate in...

09/23/2008 08:07 PM

Biotechnologies in Italy

This report supplies information on the Italian market and its competitors: market trends, SWOT and Key Success Factors Analysis, major companies performance indicators (employees, total and sector specific turnover and market shares, company strategies and marketing mix, strategic and competitive positioning, profitability and financial indicators), business prospects and trends.

Competitors™ reports are available in Italian only. An abstract in English is supplied free of charge on demand.

09/19/2008 02:38 PM

Lessons Learned from the Current Crop of Biotech Startups

This report features three Spectrum Expert Commentaries—one offers insight from the perspective of a biotech startup, another offers advice from a renowned cancer biologist to young companies that want to go public or have been public and are struggling, and the other highlights an emerging area of...

09/19/2008 02:03 PM

Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances

This report features interviews with top executives and industry experts, who offer insight into current alliances and contribute to a broad perspective on the drivers of current licensing practices As the biotechnology industry continues to evolve and mature, many biotech companies are gaining more...

09/18/2008 05:19 PM

Target Analytical Report - CCKBR

The current report on CCKBR1 is a compilation of manually curated information that is derived from the following process Information is extracted from: - Public domain databases such as SwissProt, UniProt, Entrez PubMed, OMIM, etc - In-house databases - Curated information from journal articles and...

09/18/2008 05:13 PM

Target Analytical Report - ABL1

The current report on ABL1 is a compilation of manually curated information that is derived from the following process Information is extracted from: - Public domain databases such as SwissProt, UniProt, Entrez PubMed, OMIM, etc - In-house databases - Curated information from journal articles and...

09/17/2008 08:00 PM

China Biotherapeutics Database 2006

China Biotherapeutics Database 2006 contains:Comprehensive Listing of Biopharmaceuticals in China; unique listing of all Chinese Biopharmaceuticals Included are protein therapeutics, vaccines, recombinant hormones, recombinant growth factors, biotechnology-related diagnostics, and many others...

09/17/2008 07:49 PM

Commercialization of Life Sciences, a Survey of Marketing and Sales Executives

Survey results from 100 biomanufacturing life science marketers Covers current problems associated with commercializing biotechnology and life sciences products, education, training needs, requirements for ensuring effective commercialization...

09/16/2008 03:23 PM

Stem Cells in Regenerative Medicine 2008 Market Report

This is the latest and most up-to-date Worldwide Stem Cells Market Report This report focuses on the worldwide Regenerative Medicine/Cellular Therapy Marketplace which is a major segment of the overall stem cells space The industry coverage in this report focuses on the technical aspects of stem...

Home \| Business \| Internet \| Chess \| Charity \| Biotechnology \| Investment \| Economy \| Environment \| Health \| Education \| International trade
Powered by - vSplash	© 2007 Armand Rousso Biotechnology News. All Rights Reserved.